Case Details

Year Initiated/Committed

2019

Settlement Amount

n/a

Court

U.S. District Court for the District of Pennsylvania

Docket Number

2:19-CV-02407

Lead State

CT, FL, NY

Participating States

AK, AL, AZ, CO, CT, DE, FL, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NJ, NM, NV, NY, OH, OK, OR, PA, PR, RI, SC, TN, UT, VA, VT, WA, WI, WV

Defendant(s)

Teva Pharmaceuticals USA, Inc.; Actavis Holdco Us, Inc.; Actavis Pharma, Inc.; Amneal Pharmaceuticals, Inc.; Apotex Corp.; Ara Aprahamian; Aurobindo Pharma U.S.A., Inc.; David Berthold; Breckenridge Pharmaceutical, Inc.; James (Jim) Brown; Maureen Cavanaugh; Tracy Sullivan Divalerio; Dr. Reddy’s Laboratories, Inc.; Marc Falkin; Glenmark Pharmaceuticals, Inc., USA; James (Jim) Grauso; Kevin Green; Greenstone LLC; Armando Kellum; Lannett Company, Inc.; Lupin Pharmaceuticals, Inc.; Mylan Pharmaceuticals Inc.; Jill Nailor; James (Jim) Nesta; Par Pharmaceutical Companies, Inc.; Nisha Patel; Pfizer, Inc.; Konstantin Ostaficiuk; David Rekenthaler; Richard (Rick) Rogerson; Sandoz, Inc.; Taro Pharmaceuticals USA, Inc. Upsher-Smith Laboratories, Llc; Wockhardt USA LLC; Zydus Pharmaceuticals (USA), Inc.

Case Description

44 plaintiff states filed suit against Teva Pharmaceuticals and 19 of the nation’s largest generic drug manufacturers alleging a broad conspiracy to artificially inflate and manipulate prices, reduce competition and unreasonably restrain trade for more than 100 different generic drugs. The lawsuit was originally Connecticut, was transferred to the MDL court in Pennsylvania.  The lawsuit also names 15 individual senior executive defendants who were responsible for sales, marketing, pricing and operations. According to the complaint, the alleged schemes increased prices affecting the health insurance market, taxpayer-funded healthcare programs like Medicare and Medicaid, and individuals. The complaint alleges that Teva, Sandoz, Mylan, Pfizer and 16 other generic drug manufacturers engaged in a broad, coordinated and systematic campaign to conspire with each other to fix prices, allocate markets and rig bids for more than 100 different generic drugs. The drugs span all types, including tablets, capsules, suspensions, creams, gels, ointments, and classes, including statins, ace inhibitors, beta blockers, antibiotics, anti-depressants, contraceptives, non-steroidal anti-inflammatory drugs, and treat a range of diseases and conditions from basic infections to diabetes, cancer, epilepsy, multiple sclerosis, HIV, ADHD, and more. In some instances, the coordinated price increases were over 1,000 percent.